Oseltamivir (Tamiflu) must be given within 48 hours of influenza symptom onset to be effective. The pharmacological basis is:

• A Oseltamivir degrades in vivo after 48 hours rendering it inactive
• B Oseltamivir inhibits neuraminidase preventing release of new virions; after 48 hours viral replication has peaked and spread is established beyond reversal ✓
• C The host inflammatory response after 48 hours neutralizes the drug before it reaches virus-infected cells
• D Viral hemagglutinin undergoes conformational change after 48 hours reducing oseltamivir's indirect effect

Explanation

Neuraminidase cleaves sialic acid residues on host cells, releasing newly assembled influenza virions to infect adjacent cells. Oseltamivir phosphate (active form of the prodrug oseltamivir) competitively inhibits neuraminidase, trapping virions at the cell surface and limiting viral spread. After 48 hours, viral replication has already peaked, viral burden is high, and most secondary infections are established, diminishing the clinical benefit of limiting further spread. Early treatment shortens duration and reduces complication risk.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.